An Ukrinform reporter attended a unique heart surgery performed on a newborn just minutes after a cesarean section — ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...

Medically reviewed by Jeffrey S. Lander, MD "Heart disease" is a general term for problems with the heart and can be ...

BrightHeart's revolutionary AI ultrasound software has received FDA clearance, transforming fetal heart monitoring for ...

In today’s world, many people are curious about which careers offer the highest salaries. Understanding the top-paying jobs ...

Survivors of cardiovascular disease, which is the number one killer in the Cayman Islands, were honoured recently by the ...

Vetmedin Solution from Boehringer Ingelheim is indicated for treatment of cases caused by myxomatous mitral valve disease or ...

A 10-month-old boy named Vrish miraculously recovers from end-stage heart failure following a life-saving heart transplant.

President Joe Biden is set to sign the Congenital Heart Reauthorization Act Nov. 22, extending and expanding the CDC's National Congenital Heart Disease Research, Surveillance and Awareness Program.

Discover the incredible story of a 10-month-old baby from Bengaluru who overcame end-stage heart failure through a rare heart ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the ...